F
Frank Gieseler
Researcher at University of Lübeck
Publications - 117
Citations - 3425
Frank Gieseler is an academic researcher from University of Lübeck. The author has contributed to research in topics: Idarubicin & Topoisomerase. The author has an hindex of 28, co-authored 115 publications receiving 3016 citations. Previous affiliations of Frank Gieseler include University of Münster & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
Volker Heinemann,D. Quietzsch,Frank Gieseler,Michael Gonnermann,Herbert Schönekäs,Andreas Rost,Horst Neuhaus,Caroline Haag,Michael R. Clemens,Bernard Heinrich,Ursula Vehling-Kaiser,Martin Fuchs,Doris Fleckenstein,Wolfgang Gesierich,Dirk Uthgenannt,Hermann Einsele,Axel Holstege,Axel Hinke,Andreas Schalhorn,Ralf Wilkowski +19 more
TL;DR: Results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin as first-line chemotherapy for locally advanced or metastatic pancreatic cancer.
Journal ArticleDOI
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Wen Guo Jiang,Andrew James Sanders,Masaru Katoh,H. Ungefroren,Frank Gieseler,Mark E. Prince,Sarah K. Thompson,Massimo Zollo,Daniela Spano,P. Dhawan,Daniel Sliva,Pochi R. Subbarayan,Malancha Sarkar,Kanya Honoki,Hiromasa Fujii,Alexandros G. Georgakilas,Amedeo Amedei,Elena Niccolai,Amr Amin,S. Salman Ashraf,Lin Ye,William G. Helferich,Xujuan Yang,Chandra S. Boosani,Gunjan Guha,Maria Rosa Ciriolo,Katia Aquilano,Sophie Chen,Asfar S. Azmi,W N Keith,Alan Bilsland,Dipita Bhakta,Dorota Halicka,Somaira Nowsheen,Francesco Pantano,Daniele Santini +35 more
TL;DR: This review lists the disruption of E-cadherin and tight junctions, key signaling pathways, including urokinase type plasminogen activator (uPA), phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene (PI3K/AKT), focal adhesion kinase (FAK), β-catenin/zinc finger E-box binding homeobox 1 (ZEB
Journal ArticleDOI
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Keith I. Block,Charlotte Gyllenhaal,Leroy Lowe,Amedeo Amedei,A.R.M. Ruhul Amin,Amr Amin,Katia Aquilano,Jack L. Arbiser,Jack L. Arbiser,Alexandra Arreola,Alla Arzumanyan,S. Salman Ashraf,Asfar S. Azmi,Fabian Benencia,Dipita Bhakta,Alan Bilsland,Anupam Bishayee,Stacy W. Blain,Penny B. Block,Chandra S. Boosani,Thomas E. Carey,Amancio Carnero,Marianeve Carotenuto,Stephanie C. Casey,Mrinmay Chakrabarti,Rupesh Chaturvedi,Georgia Zhuo Chen,Helen Chen,Sophie Chen,Yi Charlie Chen,Beom K. Choi,Maria Rosa Ciriolo,Helen M. Coley,Andrew Collins,Marisa Connell,Sarah Crawford,Colleen S. Curran,Charlotta Dabrosin,Giovanna Damia,Santanu Dasgupta,Ralph J. DeBerardinis,William K. Decker,Punita Dhawan,Anna Mae Diehl,Jin-Tang Dong,Q. Ping Dou,Janice E. Drewa,Eyad Elkord,Bassel F. El-Rayes,Mark A. Feitelson,Dean W. Felsheru,Lynnette R. Ferguson,Carmela Fimognari,Gary L. Firestone,Christian Frezza,Hiromasa Fujii,Mark M. Fuster,Daniele Generali,Alexandros G. Georgakilas,Frank Gieseler,Michael Gilbertson,Michelle F. Green,Brendan Grue,Gunjan Guhal,Dorota Halicka,William G. Helferich,Petr Heneberg,Patricia Hentosh,Matthew D. Hirschey,Lorne J. Hofseth,Randall F. Holcombe,Kanya Honoki,Hsue-Yin Hsu,Gloria S. Huang,Lasse Jensen,Lasse Jensen,Wen Guo Jiang,Lee W. Jones,Phillip Karpowicz,W. Nicol Keith,Sid P. Kerkar,Gazala Khan,Mahin Khatami,Young Hee Ko,Omer Kucuk,Rob J. Kulathinal,Nagi B. Kumar,Byoung S. Kwon,Anne Leb,Michael A. Leab,Ho Young Lee,Terry Lichtor,Liang Tzung Lin,Jason W. Locasale,Balakrishna L. Lokeshwar,Valter D. Longo,Costas A. Lyssiotis,Karen L. MacKenzie,Meenakshi Malhotra,Maria Marino,María L. Martínez-Chantar,Ander Matheu,Christopher Maxwellx,Eoin McDonnell,Alan K. Meeker,Mahya Mehrmohamadi,Kapil Mehta,Gregory A. Michelotti,Ramzi M. Mohammad,Sulma I. Mohammed,D. James Morré,Irfana Muqbil,Vinayak Muralidharcq,Vinayak Muralidharcq,Michael P. Murphy,Ganji Purnachandra Nagaraju,Rita Nahta,Elena Niccolai,Somaira Nowsheen,Carolina Panis,Francesco Pantano,Virginia R. Parslow,Graham Pawelec,Peter L. Pedersen,Brad Poore,Deepak Poudyal,Satya Prakash,Mark E. Prince,Lizzia Raffaghello,Jeffrey C. Rathmell,W. Kimryn Rathmell,Swapan K. Ray,Jörg Reichrath,Sarallah Rezazadeh,Domenico Ribatti,Luigi Ricciardiello,R. Brooks Robeydf,R. Brooks Robeydf,Francis Rodierdh,H.P. Vasantha Rupasinghe,Gian Luigi Russo,Elizabeth P. Ryan,Abbas Samadi,Isidro Sánchez-García,Andrew James Sanders,Daniele Santini,Malancha Sarkar,Tetsuro Sasada,Neeraj K. Saxena,Rodney E. Shackelford,H. M. C. Shantha Kumara,Dipali Sharma,Dong M. Shin,David Sidransky,Markus D. Siegelin,Emanuela Signori,Neetu Singh,Sharanya Sivanand,Daniel Sliva,Carl Smythe,Carmela Spagnuolo,Diana M. Stafforini,John Stagg,Pochi R. Subbarayan,Tabetha Sundin,Wamidh H. Talib,Sarah K. Thompson,Phuoc T. Tran,Hendrik Ungefroren,Matthew G. Vander Heiden,Vasundara Venkateswaran,Dass S. Vinay,Panagiotis J. Vlachostergios,Zongwei Wang,Kathryn E. Wellen,Richard L. Whelan,Eddy S. Yang,Huanjie Yang,Xujuan Yang,Paul Yaswen,Clement G. Yedjou,Xin Yin,Jiyue Zhu,Massimo Zollo +183 more
TL;DR: An international task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms, and results suggest that a broad-spectrums approach should be feasible from a safety standpoint.
Journal ArticleDOI
Culprit and victim -- DNA topoisomerase II.
TL;DR: The degree of topoisomerase II expression in tumours may predict the clinical course and responsiveness to therapy, and the combined use of top Loisomerase-inhibiting drugs with different mechanisms of action promises to improve particular treatment designs.
Journal ArticleDOI
Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impact
TL;DR: This review summarizes current information about PAR-initiated physical and functional receptor interactions and their physiological and pathological roles and focuses especially on PAR homo- and heterodimerization, transactivation of receptor tyrosine kinases (RTKs) and receptor serine/threonine kinase (RSTKs), communication with other GPCRs, toll-like receptors and NOD- like receptors, ion channel receptors, and on PAR association with cargo receptors.